Benefits of Taurisolo in Diabetic Patients with Peripheral Artery Disease

• Published in: Journal of cardiovascular development and disease Vol. 11; no. 6; p. 174
• Main Authors: Amato, Bruno, Novellino, Ettore, Morlando, Davide, Vanoli, Camilla, Vanoli, Emilio, Ferrara, Fulvio, Difruscolo, Rossana, Goffredo, Vito Maria, Compagna, Rita, Tenore, Gian Carlo, Stornaiuolo, Mariano, Fordellone, Mario, Caradonna, Eugenio
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2024; MDPI
• Subjects: Acids; Aspirin; Asymptomatic; Atherosclerosis; Care and treatment; Chronic illnesses; claudication; Clopidogrel; Development and progression; Diabetes; Diabetics; Diseases; Exercise; Health aspects; Intermittent claudication; Ischemia; Patients; peripheral artery disease (PAD); Polyphenols; Quality of life; Software; Taurisolo; trimethyl-N-oxide (TMAO); Vein & artery diseases; United States > US; Taurisolo; trimethyl-N-oxide (TMAO); claudication; diabetes; peripheral artery disease (PAD)
• ISSN: 2308-3425; 2308-3425
• DOI: 10.3390/jcdd11060174

Trimethyl- -oxide (TMAO) has been linked to peripheral artery disease (PAD). Taurisolo is a natural, balanced phytocomplex containing resveratrol, quercetin, catechins, procianidins, gallic acid, and caffeic acid. Numerous studies have shown that Taurisolo reduces the damage of TMAO and exerts a protective effect on endothelial cells (ECs). The aim of this randomized, double-blind, single-center study was to evaluate the effects of Taurisolo on claudication in patients with PAD (Rutheford grade I, category II, Fontaine Classification: Stage IIA, American Medical Association Whole Person Impairment Classification: Class 0-WPI 0%) in two parallel groups of 31 patients. The primary outcomes were an increase in the pain-free walking distance and the ankle/brachial pressure index at the beginning and at the end of the treatment with Taurisolo. The secondary endpoint was the serum TMAO changes. The claudication distance improved by 14.1% in the Taurisolo group and by 2.0% in the placebo group, while the maximal distance increased by 15.8% and 0.6% only, respectively (both < 0.05). The TMAO plasma levels decreased from 3.97 ± 2.13 micromole/L to 0.87 ± 0.48 ( < 0.0001) in the treated group. All these changes were highly significant both in univariate mixed models as well as in the adjusted model. Ultimately, Taurisolo might be an effective intervention to ameliorate intermittent claudication.